506 related articles for article (PubMed ID: 19807670)
1. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
2. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.
Chhabra A; Yang L; Wang P; Comin-Anduix B; Das R; Chakraborty NG; Ray S; Mehrotra S; Yang H; Hardee CL; Hollis R; Dorsky DI; Koya R; Kohn DB; Ribas A; Economou JS; Baltimore D; Mukherji B
J Immunol; 2008 Jul; 181(2):1063-70. PubMed ID: 18606658
[TBL] [Abstract][Full Text] [Related]
3. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
4. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.
Soto CM; Stone JD; Chervin AS; Engels B; Schreiber H; Roy EJ; Kranz DM
Cancer Immunol Immunother; 2013 Feb; 62(2):359-69. PubMed ID: 22926060
[TBL] [Abstract][Full Text] [Related]
5. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
Wang RF
Trends Immunol; 2001 May; 22(5):269-76. PubMed ID: 11323286
[TBL] [Abstract][Full Text] [Related]
6. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
7. [Coreceptor function of CD4 in response to MHC class I molecule].
Zvezdova ES; Grinenko TS; Pobezinskaia EL; Pobezinskiĭ LA; Kazanskiĭ DB
Mol Biol (Mosk); 2008; 42(4):662-72. PubMed ID: 18856067
[TBL] [Abstract][Full Text] [Related]
8. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
9. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
10. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
[TBL] [Abstract][Full Text] [Related]
11. Suppression of inducible CD4 regulatory cells by MHC class I-restricted human tumor epitope specific TCR engineered multifunctional CD4 T cells.
Chhabra A; Mukherji B
Hum Immunol; 2016 Oct; 77(10):905-911. PubMed ID: 27320826
[TBL] [Abstract][Full Text] [Related]
12. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
13. Human tumor antigens: implications for cancer vaccine development.
Wang RF
J Mol Med (Berl); 1999 Sep; 77(9):640-55. PubMed ID: 10569202
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
15. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
16. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Ray S; Chhabra A; Chakraborty NG; Hegde U; Dorsky DI; Chodon T; von Euw E; Comin-Anduix B; Koya RC; Ribas A; Economou JS; Rosenberg SA; Mukherji B;
Clin Immunol; 2010 Sep; 136(3):338-47. PubMed ID: 20547105
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
18. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
19. The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope.
Han X; Ye P; Luo L; Zheng L; Liu Y; Chen L; Wang S
Cell Mol Immunol; 2011 Jul; 8(4):333-40. PubMed ID: 21643003
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
